Effectiveness and safety of herbal medicine for cancer‐related fatigue in lung cancer survivors: A systematic review and meta‐analysis

Approximately half of lung cancer patients (LCP) receiving chemotherapy are experiencing cancer‐related fatigue (CRF). In East Asia, herbal medicines (HMs) have been used as tonics due to their anti‐fatigue effect. This systematic review evaluated the effectiveness and safety of HMs for CRF in LCP. We comprehensively searched 12 electronic medical databases to search randomized controlled trials (RCTs) and quasi‐RCTs investigating HMs for CRF in LCP, published up to September 2019. The primary outcome was the fatigue severity. Secondary outcomes included patients' quality of life (QOL), activities of daily life (ADL), and incidence of adverse events. Cochrane's risk of bias tool assessed the methodological quality of included RCTs. The risk ratio or mean difference was estimated with 95% confidence intervals by performing a meta‐analysis. Twelve RCTs with 861 participants were included. Compared to conventional medicine alone, HM combined with conventional medicine significantly improved fatigue level, QOL, and ADL. As monotherapy, HM significantly improved ADL compared with megestrol. No serious HM‐related adverse events were reported. Limited evidence suggests that HM could be effective and safe for CRF in LCP. However, further high‐quality RCTs are needed to confirm these findings owing to the small number and low methodological quality of the included studies.